PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
61.285 USD
+0.7 (+1.16%)
Taking everything into account, PBH scores 6 out of 10 in our fundamental rating. PBH was compared to 191 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of PBH (6.21%) is better than 88.48% of its industry peers.
PBH has a better Return On Equity (11.48%) than 86.91% of its industry peers.
The Return On Invested Capital of PBH (7.95%) is better than 85.86% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBH is significantly below the industry average of 15.35%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH's Profit Margin of 19.02% is amongst the best of the industry. PBH outperforms 92.15% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH has a better Operating Margin (31.15%) than 94.24% of its industry peers.
PBH's Operating Margin has been stable in the last couple of years.
PBH's Gross Margin of 56.13% is fine compared to the rest of the industry. PBH outperforms 65.97% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
PBH has an Altman-Z score of 2.58. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of PBH (2.58) is better than 68.06% of its industry peers.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.79, PBH belongs to the best of the industry, outperforming 86.39% of the companies in the same industry.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 63.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.58 |
ROIC/WACC0.95
WACC8.41%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
PBH's Current ratio of 4.38 is fine compared to the rest of the industry. PBH outperforms 64.92% of its industry peers.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Quick ratio (2.99) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
The Revenue has been growing slightly by 1.10% in the past year.
The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.45% yearly.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.11% on average per year.
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.44 indicates a correct valuation of PBH.
Compared to the rest of the industry, the Price/Earnings ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 87.96% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PBH to the average of the S&P500 Index (26.35), we can say PBH is valued slightly cheaper.
PBH is valuated correctly with a Price/Forward Earnings ratio of 12.71.
Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 84.29% of the companies in the same industry.
PBH is valuated cheaply when we compare the Price/Forward Earnings ratio to 33.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.44 | ||
| Fwd PE | 12.71 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 87.43% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 90.05% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.26 | ||
| EV/EBITDA | 10.19 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)20.03
PEG (5Y)1.51
EPS Next 2Y3.17%
EPS Next 3Y2.82%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PBH (11/12/2025, 3:18:24 PM)
61.285
+0.7 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change-2.55%
Ins Owners1.29%
Ins Owner Change1.2%
Market Cap3.02B
Revenue(TTM)1.14B
Net Income(TTM)213.00M
Analysts84
Price Target82.42 (34.49%)
Short Float %3.39%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-3.35%
PT rev (3m)-10.02%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-18.87%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-5.34%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-11.74%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-3.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.44 | ||
| Fwd PE | 12.71 | ||
| P/S | 2.69 | ||
| P/FCF | 11.26 | ||
| P/OCF | 10.94 | ||
| P/B | 1.63 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.19 |
EPS(TTM)4.56
EY7.44%
EPS(NY)4.82
Fwd EY7.87%
FCF(TTM)5.44
FCFY8.88%
OCF(TTM)5.6
OCFY9.14%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)20.03
PEG (5Y)1.51
Graham Number62.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.58 |
F-Score8
WACC8.41%
ROIC/WACC0.95
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.48%
EBIT Next 5Y2.99%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 0.67% in the next year.